Novel Binary Drugs Against Respiratory Viruses: Combined Virus- And Host-Targeted Approach
Published in The American Journal of Public Health
O.P. Zhirnov ✉
O.P. ZhirnovCorresponding author- D.I. Ivanovsky Institute of Virology, N.F. Gamaleya Scientific Research Institute of Epidemiology and Microbiology, Moscow; Russian-German Academy of Medicosocial and Biotechnological Sciences, Moscow
Show affiliations (1)
- D.I. Ivanovsky Institute of Virology, N.F. Gamaleya Scientific Research Institute of Epidemiology and Microbiology, Moscow; Russian-German Academy of Medicosocial and Biotechnological Sciences, Moscow
Published
Abstract
Influenza and coronaviruses are relevant respiratory infections that cause significant damage to people's health and healthcare systems. Modern antiviral drugs with direct viral action (VTA - virus-targeting action) have several disadvantages related to (i) a narrow spectrum of antiviral action, (ii) the rapid appearance of drug-resistant mutants, (iii) a lack of drug action to suppress the pathogenesis of viral diseases, and (iv) high therapeutic dosages and side effects. This minireview focuses on the design of drugs that target both viral (VTA) and cellular pathogenetic mechanisms (HTA - host-targeting action). This type of binary drug is designed to overcome the above limitations of the monotarget approach. An effective binary drug combining aprotinin, a natural polypeptide protease inhibitor, and ribavirin, a nucleoside analogue interfering with viral polymerase, is considered. Aerosol inhalations of this combined formulation were found to prevent virus dissemination and develop high therapeutic efficacy in mice infected with the highly pathogenic H7N2 avian influenza virus. This type of pharmaceutical formulation is applicable for aerosol delivery using a propellant metered-dose inhaler in patients at the earliest signs of respiratory infection. Thus, binary antiviral drugs open a promising avenue for creating reliable drugs to combat new, unknown viral threats of future highly pathogenic viral diseases "X".
Minireview#
1 Actuality of Respiratory Virus Infections#
Respiratory viral infections continue to be a leading cause of acute illness, contributing to the global healthcare burden, particularly for infants, the elderly and immunocompromised individuals. Among these infections, the most prevalent are those caused by influenza viruses, coronaviruses, respiratory syncytial virus, human rhinoviruses, and human paramyxoviruses. Over the last decade, lower respiratory tract infections have caused 2–3 million deaths worldwide annually[1]. Additionally, there is a potential medical threat: the emergence of novel, unknown, and dangerous pathogens, such as highly pathogenic avian influenza viruses, severe acute respiratory syndrome coronaviruses, monkeypox virus, and others[2, 3]. The above-mentioned facts highlight the need for broad-spectrum antiviral strategies to design effective universal drugs for easy use in family and clinical practice as a first line of defense for the human population and attending physicians against such highly pathogenic viruses. For example, mortality risks of highly pathogenic influenza viruses of the H5 subtype in humans are estimated at >50%[4, 5], which is similar to the Spanish flu pandemic situation in 1918–1919, with 50–100 million deaths globally[6]. Thus, respiratory viral infections and future pandemics are major global public healthcare problems, and healthcare systems must remain prepared on a global scale for potential viral mutations that can alter viral adaptation and pathogenicity for humans, increase viral transmission patterns from birds and animals to the human population, and initiate the pandemic process.
5 Conclusion#
(i) The respiratory infection process caused by viruses, such as influenza viruses, coronaviruses, paramyxoviruses, etc., develops through the mechanism of a “vicious cycle”. The virus activates host proteases, and upregulated proteases activate virus-dependent cell fusion and infectivity of the synthesized virus to promote the spread of infection. On the other hand, cell damage and an overbalance of host proteases, such as plasmin, kallikrein, thrombin, transmembrane serine proteases, PAR1, TMPRSS2, TMPRSS13, uPA, matriptase, tissue plasminogen activator, etc., provoke pathogenic inflammatory processes, lung edema, hyperactive coagulation, thrombosis, and other pathogenic mechanisms.
(ii) The exogenous protease inhibitor aprotinin, which suppresses a wide spectrum of proteases, normalizes the host proteolytic balance, decreases the spread of viral infection and the development of inflammation, and provides a marked therapeutic effect.
(iii) A combination of virus-targeted and host-targeted drugs, known as binary drugs, for example, ribavirin, an inhibitor of viral polymerases, and aprotinin, a protease inhibitor, provides protection against highly pathogenic avian influenza virus at low drug dosages and prevents virus dissemination throughout the infected organism.
(iv) These binary drug combinations, possessing a wide spectrum of antiviral activity, are proposed for use in hand-held metered-dose inhalers (MDIs) as effective drugs for the first line of defense against future new, unknown highly pathogenic viruses, referred to as diseases “X”.
(v) The global healthcare system must remain prepared for the high potential risks of natural virus “X” mutations that can dramatically increase viral pathogenicity in humans and viral transmission from birds and animals to the human population, thereby initiating a new pandemic process.
Declarations
€Funding
◎Competing interests
♥Acknowledgements
Article information
- Published
Copyright © 2026 Prof. O.P. Zhirnov. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. CC BY 4.0 · Corrections policy
References 80#
- 1
World Health Organization The Top 10 Causes of Death. Aug, 2024. (accessed on 12 September 2024). Available online: https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death.
- 2
Simpson S, Kaufmann MC, Glozman V, Chakrabarti A. Disease X: accelerating the development of medical countermeasures for the next pandemic. Lancet Infect Dis. 2020 May;20(5):e108-115. doi: 10.1016/S1473-3099(20)30123-7. Epub 2020 Mar 17. Erratum in: Lancet Infect Dis. 2020 Dec; 20(12):e298. doi: 10.1016/S1473-3099(20)30829-X. PMID: 32197097; PMCID: PMC7158580.
- 3
Jiang S, Shi ZL. The First Disease X is Caused by a Highly Transmissible Acute Respiratory Syndrome Coronavirus. Virol Sin. 2020 Jun;35(3):263-265. doi: 10.1007/s12250-020-00206-5. Epub 2020 Feb 14. PMID: 32060789; PMCID: PMC7091198.
- 4
Shi J, Zeng X, Cui P, Yan C, Chen H. Alarming situation of emerging H5 and H7 avian influenza and effective control strategies. Emerg Microbes Infect. 2023 Dec;12(1):2155072. doi: 10.1080/22221751.2022.2155072. PMID: 36458831; PMCID: PMC9754034.
- 5
Zhirnov OP, Lvov DK. Avian flu: «for whom the bell tolls»? Vopr Virusol. 2024May 6;69(2):101-118. doi: 10.36233/10.36233/0507-4088-213. PMID: 38843017.
- 6
Johnson NP, Mueller J. Updating the accounts: global mortality of the 1918-1920 "Spanish" influenza pandemic. Bull Hist Med. 2002 Spring;76(1):105-15. doi: 10.1353/bhm.2002.0022. PMID: 11875246.
- 7
Hayden FG, Shindo N. Influenza virus polymerase inhibitors in clinical development. Curr Opin Infect Dis. 2019 Apr;32(2):176-186. doi: 10.1097/QCO.0000000000000532. PMID: 30724789; PMCID: PMC6416007.
- 8
Zhirnov O.P., Chernyshova A.I. Favipiravir: the hidden threat of mutagenic action. Journal of microbiology, epidemiology and immunobiology. 2021; 98(2): 213–220. DOI: https://doi.org/10.36233/0372-9311-114
- 9
Beigel JH, Hayden FG. Influenza Therapeutics in Clinical Practice-Challenges and Recent Advances. Cold Spring Harb Perspect Med. 2021 Apr 1;11(4):a038463. doi: 10.1101/cshperspect.a038463. PMID: 32041763; PMCID: PMC8015700.
- 10
Batool S, Chokkakula S, Song MS. Influenza Treatment: Limitations of Antiviral Therapy and Advantages of Drug Combination Therapy. Microorganisms. 2023 Jan 11;11(1):183. doi: 10.3390/microorganisms11010183. PMID: 36677475; PMCID: PMC9865513.
- 11
Luong QXT, Hoang PT, Ho PT, Ayun RQ, Lee TK, Lee S. Potential Broad-Spectrum Antiviral Agents: A Key Arsenal Against Newly Emerging and Reemerging Respiratory RNA Viruses. Int J Mol Sci. 2025 Feb 10;26(4):1481. doi: 10.3390/ijms26041481. PMID: 40003946; PMCID: PMC11855616.
- 12
Bayurova E, Kostyushev D, Tikhonov A, Chulanov V, Gordeychuk I. Broad-acting antivirals: the pursuit of pan-viral therapeutics in the era of pandemics. J Virol. 2026 Mar 23:e0007726. doi: 10.1128/jvi.00077-26. Epub ahead of print. PMID: 41870078.
- 13
Sanjuán R, Domingo-Calap P. Mechanisms of viral mutation. Cell Mol Life Sci. 2016 Dec;73(23):4433-4448. doi: 10.1007/s00018-016-2299-6. Epub 2016 Jul 8. PMID: 27392606; PMCID: PMC5075021.
- 14
Ison MG, Hayden FG, Hay AJ, Gubareva LV, Govorkova EA, Takashita E, McKimm- Breschkin JL. Influenza polymerase inhibitor resistance: Assessment of the current state of the art - A report of the isirv Antiviral group. Antiviral Res. 2021 Oct;194:105158. doi: 10.1016/j.antiviral.2021.105158. Epub 2021 Aug 4. PMID: 34363859; PMCID: PMC9012257.
- 15
Sepúlveda CS, García CC, Damonte EB. Inhibitors of Nucleotide Biosynthesis as Candidates for a Wide Spectrum of Antiviral Chemotherapy. Microorganisms. 2022 Aug 12;10(8):1631. doi: 10.3390/microorganisms10081631. PMID: 36014049; PMCID: PMC9413629.
- 16
Roa-Linares VC, Escudero-Flórez M, Vicente-Manzanares M, Gallego-Gómez JC. Host Cell Targets for Unconventional Antivirals against RNA Viruses. Viruses. 2023 Mar 17;15(3):776. doi: 10.3390/v15030776. PMID: 36992484; PMCID: PMC10058429.
- 17
Schreiber A, Ludwig S. Host-targeted antivirals against SARS-CoV-2 in clinical development - Prospect or disappointment? Antiviral Res. 2025 Mar;235:106101. doi: 10.1016/j.antiviral.2025.106101. Epub 2025 Feb 7. PMID: 39923941.
- 18
Chen Y, Shi Y, Zuo X, Dong X, Xiao X, Chen L, Xiang Z, Ren L, Zhou Z, Wei W, Lei X, Wang J. UNC0638 inhibits SARS-CoV-2 entry by blocking cathepsin L maturation. J Virol. 2025 Jul 22;99(7):e0074125. doi: 10.1128/jvi.00741-25. Epub 2025 Jun 18. PMID: 40530850; PMCID: PMC12282183.
- 19
Alalem N, Alalem M, Awad A, Elshamy AM, Elalem OR, Tabl AM, Ebaid ME, Khalil H. A novel mechanistic study on inhibiting influenza A virus replication by a newly extracted polypeptide targeting host autophagy. Arch Microbiol. 2025 Sep 18;207(11):267. doi: 10.1007/s00203-025-04476-z. PMID: 40965660.
- 20
Zhirnov OP, Klenk HD, Wright PF. Aprotinin and similar protease inhibitors as drugs against influenza. Antiviral Res. 2011 Oct;92(1):27-36. doi:10.1016/j.antiviral.2011.07.014. Epub 2011 Jul 23. PMID: 21802447.
- 21
de León P, Cañas-Arranz R, Bustos MJ, Sáiz M, Sobrino F. Inhibition of Human Coronaviruses by Combinations of Host-Targeted and Direct-Acting Antivirals. Antimicrob Agents Chemother. 2023 Apr 18;67(4):e0170322. doi: 10.1128/aac.01703-22. Epub 2023 Mar 28. PMID: 36975844; PMCID: PMC10112268.
- 22
Ludwig S, Pleschka S, Planz O. MEK inhibitors as novel host-targeted antivirals with a dual-benefit mode of action against hyperinflammatory respiratory viral diseases. Curr Opin Virol. 2023 Apr; 59:101304. doi: 10.1016/j.coviro.2023.101304. Epub 2023 Feb 24. PMID: 36841033; PMCID: PMC10091867.
- 23
Beran RK, Vijjapurapu A, Nair V, Du Pont V. Host-targeted antivirals as broad-spectrum inhibitors of respiratory viruses. Curr Opin Virol. 2025 Dec;73:101492. doi: 10.1016/j.coviro.2025.101492. Epub 2025 Oct 1. PMID: 41037996.
- 24
Wang Y, Wang X, Doğan T, Sam-Agudu NA, Al-Tawfiq JA, Pan Q. Mpox: disease manifestations and therapeutic development. J Virol. 2025 Sep 23;99(9):e0015225. doi: 10.1128/jvi.00152-25. Epub 2025 Aug 11. PMID: 40787989; PMCID: PMC12459235.
- 25
Schwartz RS. Paul Ehrlich's magic bullets. N Engl J Med. 2004 Mar 11;350(11):1079-80. doi: 10.1056/NEJMp048021. PMID: 15014180.
- 26
Fritz H, Wunderer G. Biochemistry and applications of aprotinin, the kallikrein inhibitor from bovine organs. Arzneimittelforschung. 1983;33(4):479-94. PMID: 6191764.
- 27
Wegner J. Biochemistry of serine protease inhibitors and their mechanisms of action: a review. J Extra Corpor Technol. 2003 Dec;35(4):326-38. PMID: 14979425.
- 28
Zhirnov OP, Ikizler MR, Wright PF. Cleavage of influenza a virus hemagglutinin in human respiratory epithelium is cell associated and sensitive to exogenous antiproteases. J Virol. 2002 Sep;76(17):8682-9. doi: 10.1128/jvi.76.17.8682-8689.2002. PMID: 12163588; PMCID: PMC136409.
- 29
Zhirnov OP, Matrosovich TY, Matrosovich MN, Klenk HD. Aprotinin, a protease inhibitor, suppresses proteolytic activation of pandemic H1N1v influenza virus. Antivir Chem Chemother. 2011 Mar 7;21(4):169-74. doi: 10.3851/IMP1715.
- 30
Böttcher-Friebertshäuser E, Garten W, Matrosovich M, Klenk HD. The hemagglutinin: a determinant of pathogenicity. Curr Top Microbiol Immunol. 2014;385:3-34. doi: 10.1007/82_2014_384. PMID: 25031010
- 31
Hoffmann M, Kleine-Weber H, Schroeder S. et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020 Apr 16;181(2):271-280.e8. doi: 10.1016/j.cell.2020.02.052. Epub 2020 Mar 5. PMID: 32142651; PMCID: PMC7102627.
- 32
Bojkova D, Bechtel M, McLaughlin KM, McGreig JE. Et al. Aprotinin Inhibits SARS-CoV-2 Replication. Cells. 2020 Oct 30;9(11):2377. doi: 10.3390/cells9112377. PMID: 33143316; PMCID: PMC7692688.
- 33
Kaur U, Chakrabarti SS, Ojha B, Pathak BK, Singh A, Saso L, Chakrabarti S. Targeting Host Cell Proteases to Prevent SARS-CoV-2 Invasion. Curr Drug Targets. 2021;22(2):192-201. doi: 10.2174/1389450121666200924113243. PMID: 32972339.
- 34
Presley efficacy against SARS-CoV-2 (JN.1) and influenza A (H1N1) viruses protect mice from influenza A infection. Emerg Microbes Infect. 2026 Dec;15(1):2616944. doi: 10.1080/22221751.2026.2616944. Epub 2026 Jan 30. PMID: 41612887; PMCID: PMC12862872.
- 35
Zhirnov OP. The phenomenon of proteolytic activation of myxoviruses and a new strategy for treating viral diseases. Vopr Virusol. 1983 Jul-Aug;28(4):9-21. Russian. PMID: 6314677.
- 36
Ascenzi P, Bocedi A, Bolognesi M, Spallarossa A, Coletta M, De Cristofaro R,Menegatti E. The bovine basic pancreatic trypsin inhibitor (Kunitz inhibitor): a milestone protein. Curr Protein Pept Sci. 2003 Jun;4(3):231-51. doi:10.2174/1389203033487180. PMID: 12769721.
- 37
Waxler B, Rabito SF. Aprotinin: a serine protease inhibitor with therapeutic actions: its interaction with ACE inhibitors. Curr Pharm Des. 2003;9(9):777-87. doi: 10.2174/1381612033455468. PMID: 12570794.
- 38
Levy JH, Sypniewski E. Aprotinin: a pharmacologic overview. Orthopedics. 2004 Jun;27(6 Suppl):s653-8. doi: 10.3928/0147-7447-20040602-05. PMID: 15239552.
- 39
Moreau ME, Garbacki N, Molinaro G, Brown NJ, Marceau F, Adam A. The kallikrein-kinin system: current and future pharmacological targets. J Pharmacol Sci. 2005 Sep;99(1):6-38. doi: 10.1254/jphs.srj05001x. PMID: 16177542.
- 40
Day JR, Landis RC, Taylor KM. Aprotinin and the protease-activated receptor 1 thrombin receptor: antithrombosis, inflammation, and stroke reduction. Semin Cardiothorac Vasc Anesth. 2006 Jun;10(2):132-42. doi: 10.1177/1089253206288997. PMID: 16959740. (Aprotinin multi: antithrombosis, antiinflammation, antistroke)
- 41
Planès C, Caughey GH. Regulation of the epithelial Na+ channel by peptidases. Curr Top Dev Biol. 2007;78:23-46. doi: 10.1016/S0070-2153(06)78002-4. PMID: 17338914; PMCID: PMC2276519.
- 42
Landis C. Pharmacologic strategies for combating the inflammatory response. J Extra Corpor Technol. 2007 Dec;39(4):291-5. PMID: 18293823; PMCID: PMC4680701.
- 43
Zhirnov O.P., Poyarkov S., Malyshev N.A. Antiviral and anti-inflammatory targets of aprotinin: Prospects for new uses. Pulmonology. 2009; (3):109-118. https://doi.org/10.18093/0869-0189-2009-3-109-118
- 44
Smith M, Kocher HM, Hunt BJ. Aprotinin in severe acute pancreatitis. Int J Clin Pract. 2010 Jan;64(1):84-92. doi: 10.1111/j.1742-1241.2008.01899.x. Epub 2009 Jan 28. PMID: 19178597.
- 45
Brown JR, Toler AW, Kramer RS, Landis RC. Anti-inflammatory effect of aprotinin: a meta-analysis. J Extra Corpor Technol. 2009 Jun;41(2):79-86. PMID: 19681304; PMCID: PMC4680210.
- 46
Padín JF, Pérez-Ortiz JM, Redondo-Calvo FJ. Aprotinin (I): Understanding the Role of Host Proteases in COVID-19 and the Importance of Pharmacologically Regulating Their Function. Int J Mol Sci. 2024 Jul 10;25(14):7553. doi: 10.3390/ijms25147553. PMID: 39062796; PMCID: PMC11277036.
- 47
Vanglabeke LLW, Rex S, Van den Eynde R. Platelet-sparing properties of aprotinin: A scoping review on mechanisms and clinical effects. Eur J Anaesthesiol. 2025 Jan 1;42(1):36-43. doi: 10.1097/EJA.0000000000002081. Epub 2024 Oct 11. PMID: 39628415.
- 48
Zhirnov OP. High protection of animals lethally infected with influenza virus by aprotinin-rimantadine combination. J Med Virol. 1987 Feb;21(2):161-7. doi: 10.1002/jmv.1890210208. PMID: 2434613; PMCID: PMC7166978.
- 49
Ovcharenko AV, Zhirnov OP. Aprotinin aerosol treatment of influenza and paramyxovirus bronchopneumonia of mice. Antiviral Res. 1994 Feb;23(2):107-18. doi: 10.1016/0166-3542(94)90038-8. PMID: 7511880.
- 50
Zhirnov OP, Kirzhner LS, Ovcharenko AV, Malyshev NA. The pathogenetic therapy of acute respiratory diseases by aprotinin inhalations. Ter Arkh. 1995; 67(6):38-42. Russian. PMID: 7545316.
- 51
Zhirnov O.P., Kirzhner L.S., Ovcharenko A.V., Malyshev N.A. Aerosolized aprotinin is an effective drug against viral respiratory illness. Antiinfective Drugs and Chemotherapy. 1996, Vol. 14, No. 3, pages 209-216.
- 52
Zhirnov OP, Bokova NO, Isaeva EI, Vorobieva IV, Malyshev NA. Pathogenetic treatment of influenza patients with aerosolized form of aprotinin, a protease inhibitor. Biopharmaceuticals (Russian) 2015; v.4: 59–64.
- 53
Redondo-Calvo FJ, Padín JF, Muñoz-Rodríguez JR, Serrano-Oviedo L. et al. Aprotinin treatment against SARS-CoV-2: A randomized phase III study to evaluate the safety and efficacy of a pan-protease inhibitor for moderate COVID-19. Eur J Clin Invest. 2022 Jun;52(6):e13776. doi: 10.1111/eci.13776. Epub 2022 Apr 5. PMID: 35342931; PMCID: PMC9111659.
- 54
Redondo-Calvo FJ, Padín JF, Martínez-Alarcón J, et al. Inhaled aprotinin reduces viral load in mild-to-moderate inpatients with SARS-CoV-2 infection. Eur J Clin Invest. 2022;52:e13850. doi: 10.1111/eci.13850
- 55
Wagoner J, Herring S, Hsiang TY, Ianevski A. et al. Combinations of Host- and Virus-Targeting Antiviral Drugs Confer Synergistic Suppression of SARS-CoV-2. Microbiol Spectr. 2022 Oct 26;10(5):e0333122. doi: 10.1128/spectrum.03331-22. Epub 2022 Oct 3. PMID: 36190406; PMCID: PMC9718484.
- 56
Kainov DE, Ravlo E, Ianevski A. Seeking innovative concepts in development of antiviral drug combinations. Antiviral Res. 2025 Feb;234:106079. doi: 10.1016/j.antiviral.2025.106079. Epub 2025 Jan 9. PMID: 39798882.
- 57
Jiang S, Shi ZL. The First Disease X is Caused by a Highly Transmissible Acute Respiratory Syndrome Coronavirus. Virol Sin. 2020 Jun;35(3):263-265. doi: 10.1007/s12250-020-00206-5. Epub 2020 Feb 14. PMID: 32060789; PMCID: PMC7091198.
- 58
Simpson S, Kaufmann MC, Glozman V, Chakrabarti A. Disease X: accelerating the development of medical countermeasures for the next pandemic. Lancet Infect Dis. 2020 May;20(5):e108-e115. doi: 10.1016/S1473-3099(20)30123-7. Epub 2020 Mar 17. Erratum in: Lancet Infect Dis. 2020 Dec;20(12):e298. doi: 10.1016/S1473-3099(20)30829-X. PMID: 32197097; PMCID: PMC7158580.
- 59
Zaman MH, Ali N and Ilyas M. 2024. “Disease X” and prevention policies. Front. Public Health 12:1303584. doi: 10.3389/fpubh.2024.1303584
- 60
Luczo JM, Spackman E. Molecular Evolution of the H5 and H7 Highly Pathogenic Avian Influenza Virus Haemagglutinin Cleavage Site Motif. Rev Med Virol. 2025 Jan;35(1):e70012. doi: 10.1002/rmv.70012. PMID: 39730318; PMCID: PMC11680514.
- 61
Neumann G, Eisfeld AJ, Kawaoka Y. Viral factors underlying the pandemic potential of influenza viruses. Microbiol Mol Biol Rev. 2025 Jun 25;89(2):e0006624. doi: 10.1128/mmbr.00066-24. Epub 2025 May 9. PMID: 40340558; PMCID: PMC12188719.
- 62
Bellido-Martín B, Rijnink WF, Iervolino M, Kuiken T, Richard M, Fouchier RAM. Evolution, spread and impact of highly pathogenic H5 avian influenza A viruses. Nat Rev Microbiol. 2026 Jan;24(1):45-60. doi: 10.1038/s41579-025-01189-4. Epub 2025 May 22. PMID: 40404976.
- 63
Virasole (ribavirin for inhalation solution, USP) prescribibg information (package insert). Bridge-water, NJ: Bauch Health US, LLC; 2019.
- 64
Virasole (ribavirin for inhalation) Solution, USP (product monograph). Leval, Quebec, Canada: Bausch Health Canada Inc; 2020.
- 65
Zhirnov OP. Molecular Targets in the Chemotherapy of Coronavirus Infection. Biochemistry (Mosc). 2020 May;85(5):523-530. doi: 10.1134/S0006297920050016. PMID: 32571182; PMCID: PMC7232917.
- 66
Messina E, Danise A, Ferrari G, Andolina A, Chiurlo M, Razanakolona M, Barakat M, Israel RJ, Castagna A. Ribavirin Aerosol in the Treatment of SARS- CoV-2: A Case Series. Infect Dis Ther. 2021 Dec;10(4):2791-2804. doi: 10.1007/s40121-021-00493-9. Epub 2021 Jul 23. PMID: 34302258; PMCID: PMC8302211.
- 67
Ivashchenko AA, Zagribelnyy BA, Ivanenkov YA, Ivashchenko IA, Karapetian RN, Kravchenko DV, Savchuk NP, Yakubova EV, Ivachtchenko AV. The Efficacy of Aprotinin Combinations with Selected Antiviral Drugs in Mouse Models of Influenza Pneumonia and Coronavirus Infection Caused by SARS-CoV-2. Molecules. 2022 Aug 5;27(15):4975. doi: 10.3390/molecules27154975. PMID: 35956925; PMCID: PMC9370800.
- 68
Zhirnov OP, Chernyshova AI. The uncleaved viral hemagglutinin HA0 increases influenza A virus resistance to thermal pasteurization. Virology. 2025 Mar;604:110389. doi: 10.1016/j.virol.2025.110389. Epub 2025 Jan 3. PMID: 39889479.
- 69
Bartlett ML, Palese P, Davis MF, Vermund SH et al. Enhancing the response to avian influenza in the US and globally. Lancet Reg Health Am. 2025 Apr 28;46:101100. doi: 10.1016/j.lana.2025.101100. PMID: 40625789; PMCID: PMC12230410.
- 70
Ganderton D, Lewis D, Davies R, Meakin B, Brambilla G, Church T. Modulite: a means of designing the aerosols generated by pressurized metered dose inhalers. Respir Med. 2002 Aug;96 Suppl D:S3-8. doi: 10.1016/s0954-6111(02)80018-x. PMID: 12201079.
- 71
Salvadori M, Singh D, Mathews K, Girardello L, Cortellini M, Emirova A, Pacchetti I, Foti M, Puviani V, Poli G, Rony F. The low global warming potential propellant HFA-152a does not induce bronchoconstriction or impair mucociliary clearance. Pulm Pharmacol Ther. 2025 Jun;89:102358. doi: 10.1016/j.pupt.2025.102358. Epub 2025 Apr 5. PMID: 40194694.
- 72
Duke DJ, Rao L, Myatt B, Cocks P, Stein S, Marasini N, Ong HX, Young P. In- vitro Evaluation of Solution Pressurised Metered Dose Inhaler Sprays with Low-GWP Propellants. Pharm Res. 2025 Feb;42(2):385-400. doi: 10.1007/s11095-025-03830-6. Epub 2025 Feb 12. PMID: 39939559; PMCID PMC11880099.
- 73
Wilkinson AJK, Smith LE, Woodcock A. Green inhalers: reducing the carbon footprint of asthma care. Curr Opin Pulm Med. 2026 May 1; 32(3): 239-244. doi: 10.1097/MCP.0000000000001252. Epub 2026 Feb 11. PMID: 41670025.
- 74
Marasini N, Rao R, Duke D, Myatt B, Cocks P, Stein SW, Traini D, Young P, Ong HX. Development and in vitro evaluation of solution-based pressurized metered- dose inhaler formulations using green propellants. J Pharm Pharmacol. 2026 Feb 6;78(2):rgag005. doi: 10.1093/jpp/rgag005. PMID: 41697881.
- 75
Singh D, Mancini L, Melis G, Cortellini M, Rostello C, Mathews KS. Safety and tolerability of the low global warming potential propellant HFA-152a in patients with asthma receiving beclometasone dipropionate/ formoterol fumarate/glycopyrronium: The TRECOS study. Respir Med. 2026 May;256:108814. doi: 10.1016/j.rmed.2026.108814. Epub 2026 Apr 6. PMID: 41951188.
- 76
“Trixeo Aerosphere” approved in the UK as first inhaled respiratory medicine using next-generation propellant with near-zero global warming potential. Accessed August 18, 2025. https://www.astrazeneca.com/media-centre/press-releases/2025/trixeo-aerosphere-approved-in-the-uk-as-first-inhaled-respiratory-medicine-using-next-generation-propellant-with-near-zero-global-warming-potential.html
- 77
Barve M. H, Shardul P. K, Munne S. S, Bendale A. R, Naphade V, Pathan V. T, Borse L. B. Metered Dose Inhalers (MDI’S) for High-Performance Pulmonary Drug Delivery in Assistance to Nanotechnology. Biosci Biotech Res Asia 2023;20(2). Available at: https://bit.ly/442AvCT
- 78
Weers JG, Tarara TE, Miller DP. Reimagining Carrier-Based Formulations for Inhalation: Respirable Agglomerates. J Pharm Sci. 2026 Apr 18:104289. doi: 10.1016/j.xphs.2026.104289. PMID: 42009165.
- 79
Mahmoud DE, Hosseini SH, Rathore HA, Alkilany AM, Heise A, Elhissi A. Inhalable Nanotechnology-Based Drug Delivery Systems for the Treatment of Inflammatory Lung Diseases. Pharmaceutics. 2025 Jul 9;17(7):893. doi: 10.3390/pharmaceutics17070893. PMID: 40733101; PMCID: PMC12298333.
- 80
Shaibie NA, Mohammad Faizal NDF, Buang F, Srichana T, Mohd Amin MCI. Inhaled biologics for respiratory diseases: clinical potential and emerging technologies. Drug Deliv Transl Res. 2025 Nov;15(11):4098-4114. doi: 10.1007/s13346-025-01909-6. Epub 2025 Jul 14. Erratum in: Drug Deliv Transl Res. 2026 Jan;16(1):414. doi: 10.1007/s13346-025-01985-8. PMID: 40660066; PMCID: PMC12508015.